Douglas F. Beach

Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial

Anthony R. Mato, Lindsey E. Roeker, John N. Allan et al. · American Journal of Hematology · 2018 · 72 citations · Full text

Medicine, Oncology, Pharmacology +16

A Genome-Wide Expression Analysis in Blood Identifies Pre-Elafin as a Biomarker in ARDS

Zhao‐Xi Wang, Douglas F. Beach, Li Su et al. · American Journal of Respiratory Cell and Molecular Biology · 2008 · 68 citations · Full text

Life Sciences, Molecular Biology, Molecular Medicine +9

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, Wojciech Jurczak, Ryan Jacobs et al. · Blood · 2020 · 54 citations

Medicine, Oncology, Pharmacology +12

Distinct LIN-10 Domains Are Required for Its Neuronal Function, Its Epithelial Function, and Its Synaptic Localization

Doreen R. Glodowski, Tricia M. Wright, Keri Martinowich et al. · Molecular Biology of the Cell · 2005 · 28 citations · Full text

Life Sciences, Neurobiology, Neuroscience +12

Novel Approach to Gorlin Syndrome:A Patient Treated With Oral Capecitabine

Douglas F. Beach, Robert A. Somer · Journal of Clinical Oncology · 2011 · 19 citations · Full text

Dentistry, Oral Medicine, Oral Diagnosis +2